A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a and Subcutaneous Interferon Beta-1a for the Treatment of Relapsing Multiple Sclerosis.

You Xiaojun; Coyle Patricia K.; Shang Shulian; Evilevitch Vladimir; Sabetella Guido; Werneburg Brian

首页> 外文期刊>Multiple sclerosis: clinical and laboratory research >A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a and Subcutaneous Interferon Beta-1a for the Treatment of Relapsing Multiple Sclerosis.

【24h】

A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a and Subcutaneous Interferon Beta-1a for the Treatment of Relapsing Multiple Sclerosis.

机译：匹配调整后的皮下聚乙二醇干扰素β-1a和皮下干扰素β-1a治疗复发性多发性硬化症临床疗效的间接比较。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Multiple sclerosis: clinical and laboratory research》 |2016年第3期|共1页
作者
You Xiaojun; Coyle Patricia K.; Shang Shulian; Evilevitch Vladimir; Sabetella Guido; Werneburg Brian;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学与精神病学;
关键词
入库时间 2022-08-18 12:00:44

相似文献

外文文献
中文文献
专利

1. A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a and Subcutaneous Interferon Beta-1a for the Treatment of Relapsing Multiple Sclerosis. [J] . You Xiaojun, Coyle Patricia K., Shang Shulian, Multiple sclerosis: clinical and laboratory research . 2016,第3期

机译：匹配调整后的皮下聚乙二醇干扰素β-1a和皮下干扰素β-1a治疗复发性多发性硬化症临床疗效的间接比较。
2. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (see comments) [J] . The Lancet . 1998,第9139期

机译：干扰素β-1a在复发/缓解多发性硬化症中的随机双盲安慰剂对照研究。 PRISMS（通过干扰素β-1a皮下预防多发性硬化症复发和残疾）研究组（请参阅评论）
3. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis. [J] . De Stefano N, Curtin F, Stubinski B, Multiple sclerosis: clinical and laboratory research . 2010,第7期

机译：新型皮下干扰素β-1a制剂在复发缓解型多发性硬化症中的快速收益。
4. Pre-Clinical Histologic Evaluation of a Proprietary Polyester Device for the Treatment of Dilated Cardiomyopathy (Acorn Cardiac Support Device CSD): Multiple Species Comparison [C] . Robert G. Walsh, J. Edward Shapland, Linda J. Wojcik Annual meeting of the Society For Biomaterials . 2003

机译：专有的聚酯装置治疗扩张型心肌病的临床前组织学评估（橡子心脏支持装置CSD）：多种物种比较
5. Cost-Effectiveness of Oral Agents in Relapsing-Remitting Multiple Sclerosis Compared to Interferon-Based Therapy in Saudi Arabia [D] . Alskaabi, May. 2017

机译：沙特阿拉伯口服药物在复发缓解型多发性硬化症中的成本效果与基于干扰素的疗法相比
6. Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis [O] . Martina Novotna, Ales Tvaroh, Jan Mares 2020

机译：预测治疗后未来临床疾病活性的临床参数从患有延迟多发性硬化症的患者中的其他平台注射剂转变为高剂量皮下干扰素β-1a
7. Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week [O] . Patricia K. Coyle, Shulian Shang, Zhen Xiao, 2018

机译：匹配调整的比较展示了SCPeginterferonβ-1a的更好的临床结果，每两周比每周三次SC干扰素β-1a

A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a and Subcutaneous Interferon Beta-1a for the Treatment of Relapsing Multiple Sclerosis.

著录项

相似文献

相关主题

期刊订阅